Novel Telemedicine-Delivered Prolonged Exposure Therapy for Treating PTSD in Individuals With OUD
Launched by UNIVERSITY OF VERMONT · Feb 23, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with both Opioid Use Disorder (OUD) and Posttraumatic Stress Disorder (PTSD) using telemedicine. The therapy being tested is called prolonged exposure therapy, which helps individuals confront and process their traumatic experiences to reduce PTSD symptoms. The goal of the study is to see if this remote approach can help more people attend therapy sessions and improve their PTSD symptoms compared to traditional methods.
To be eligible for the trial, participants must be at least 18 years old and have been on a stable dose of methadone or buprenorphine for at least a month. They also need to meet specific criteria for PTSD as identified by a mental health professional. Participants should not have severe mental health issues like active hallucinations or be currently pregnant. If you join the study, you can expect to receive therapy sessions via video calls, making it easier to access treatment from home. The trial is currently recruiting participants, and it aims to provide valuable insights into treating PTSD in individuals struggling with opioid use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years old
- • Maintained on a stable methadone or buprenorphine dose for \>1 month prior to the study
- • Meet current DSM-5 posttraumatic stress disorder criteria based on the Clinician Administered PTSD Scale for DSM-5
- • Participants receiving psychotropic medications must be maintained on a stable dose for \>1 month prior to enrollment.
- Exclusion Criteria:
- • Current delusions or hallucinations, unstable bipolar disorder, imminent risk for suicide as assessed by the Mini International Neuropsychiatric Interview
- • Cognitive impairment as evidenced by scores \<22 on the Videoconference-based Mini Mental Status Examination (MMSE; Folstein, et al., 1975)
- • Enrolled in another ongoing evidence-based treatment for PTSD.
- • Pregnancy as verified by pregnancy test
- • No access to cellular service
About University Of Vermont
The University of Vermont (UVM) is a leading academic institution known for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UVM leverages its diverse expertise in medicine, public health, and biomedical sciences to conduct cutting-edge clinical studies. The university aims to translate scientific findings into effective treatments and interventions, ultimately improving patient outcomes and contributing to the broader medical community. UVM's research facilities and access to a wide patient population support its mission to foster a culture of inquiry and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Burlington, Vermont, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported